Investments
544Portfolio Exits
120Funds
28Partners & Customers
5Service Providers
2About Versant Ventures
Versant Ventures is a healthcare investment firm committed to helping entrepreneurs build the healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building.
Versant Ventures Headquarter Location
One Sansome Street Suite 3630
San Francisco, California, 94104,
United States
415-801-8100
Expert Collections containing Versant Ventures
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Versant Ventures in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Research containing Versant Ventures
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Versant Ventures in 3 CB Insights research briefs, most recently on Feb 2, 2021.
Feb 2, 2021
Stealth Startup Funding Surged In 2020
Latest Versant Ventures News
Apr 19, 2022
Cimeio Therapeutics has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup established by the Uni...
Versant Ventures Investments
544 Investments
Versant Ventures has made 544 investments. Their latest investment was in Cimeio Therapeutics as part of their Series A on April 4, 2022.
Versant Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/13/2022 | Series A | Cimeio Therapeutics | $50M | Yes | 5 | |
2/9/2022 | Series C | Ventus Therapeutics | $140M | No | 15 | |
12/2/2021 | Series B | CODA Biotherapeutics | $28M | No | 6 | |
11/30/2021 | Series A | |||||
11/19/2021 | Series B |
Date | 4/13/2022 | 2/9/2022 | 12/2/2021 | 11/30/2021 | 11/19/2021 |
|---|---|---|---|---|---|
Round | Series A | Series C | Series B | Series A | Series B |
Company | Cimeio Therapeutics | Ventus Therapeutics | CODA Biotherapeutics | ||
Amount | $50M | $140M | $28M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 5 | 15 | 6 |
Versant Ventures Portfolio Exits
120 Portfolio Exits
Versant Ventures has 120 portfolio exits. Their latest portfolio exit was Minerva Surgical on October 22, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/22/2021 | IPO | 10 | |||
9/21/2021 | Acquired | 2 | |||
8/5/2021 | Acquired | 13 | |||
Date | 10/22/2021 | 9/21/2021 | 8/5/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 10 | 2 | 13 |
Versant Ventures Fund History
28 Fund Histories
Versant Ventures has 28 funds, including Versant Venture Capital VIII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
4/21/2021 | Versant Venture Capital VIII | $560M | 1 | ||
4/21/2021 | Versant Vantage II | $240M | 2 | ||
11/18/2020 | Versant Venture Capital VII | $600M | 3 | ||
8/13/2019 | Versant Voyageurs I | ||||
4/24/2018 | Versant Voyageurs I Feeder |
Closing Date | 4/21/2021 | 4/21/2021 | 11/18/2020 | 8/13/2019 | 4/24/2018 |
|---|---|---|---|---|---|
Fund | Versant Venture Capital VIII | Versant Vantage II | Versant Venture Capital VII | Versant Voyageurs I | Versant Voyageurs I Feeder |
Fund Type | |||||
Status | |||||
Amount | $560M | $240M | $600M | ||
Sources | 1 | 2 | 3 |
Versant Ventures Partners & Customers
5 Partners and customers
Versant Ventures has 5 strategic partners and customers. Versant Ventures recently partnered with Chinook Therapeutics on November 11, 2021.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
11/30/2021 | Partner | Canada | 30 , 2021 -- Chinook Therapeutics , Inc. , a biopharmaceutical company focused on the discovery , development and commercialization of precision medicines for kidney diseases , today announced the formation of SanReno , a joint venture with an investor syndicate led by Frazier Healthcare Partners , to develop , manufacture and commercialize kidney disease therapies in the People 's Republic of China , Hong Kong , Macau , Taiwan and Singapore . | 1 | |
2/15/2017 | Partner | ||||
12/12/2016 | Partner | ||||
6/23/2014 | Partner | ||||
Partner |
Date | 11/30/2021 | 2/15/2017 | 12/12/2016 | 6/23/2014 | |
|---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | Canada | ||||
News Snippet | 30 , 2021 -- Chinook Therapeutics , Inc. , a biopharmaceutical company focused on the discovery , development and commercialization of precision medicines for kidney diseases , today announced the formation of SanReno , a joint venture with an investor syndicate led by Frazier Healthcare Partners , to develop , manufacture and commercialize kidney disease therapies in the People 's Republic of China , Hong Kong , Macau , Taiwan and Singapore . | ||||
Sources | 1 |
Versant Ventures Service Providers
2 Service Providers
Versant Ventures has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Counsel | General Counsel | ||
Service Provider | ||
|---|---|---|
Associated Rounds | ||
Provider Type | Counsel | |
Service Type | General Counsel |
Partnership data by VentureSource
Versant Ventures Team
23 Team Members
Versant Ventures has 23 team members, including current Founder, Managing Director, Brian G Atwood.
Name | Work History | Title | Status |
|---|---|---|---|
Brian G Atwood | Founder, Managing Director | Current | |
Barbara N. Lubash | Crosspoint Venture Partners | Founder | Current |
Rebecca B. Robertson | Institutional Venture Partners, and Egis | Founder, Managing Director | Current |
Kristin Beach | Controller | Current | |
Candace Chan | Controller | Current |
Name | Brian G Atwood | Barbara N. Lubash | Rebecca B. Robertson | Kristin Beach | Candace Chan |
|---|---|---|---|---|---|
Work History | Crosspoint Venture Partners | Institutional Venture Partners, and Egis | |||
Title | Founder, Managing Director | Founder | Founder, Managing Director | Controller | Controller |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.